Author:
Yang Jinfu,Wang Zhengping,Fang Ying,Jiang Jing,Zhao Frances,Wong Hansen,Bennett Mark K.,Molineaux Christopher J.,Kirk Christopher J.
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Subject
Pharmaceutical Science,Pharmacology
Reference41 articles.
1. The proteasome: a suitable antineoplastic target
2. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
3. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies;Alsina;Blood (ASH Annual Meeting Abstracts),2007
4. Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
5. Development of proteasome inhibitors in oncology and autoimmune diseases;Bennett;Curr Opin Drug Discov Devel,2008
Cited by
113 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献